Search Results - "da Motta Girardi, Daniel"

Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection? by Dos Santos Fernandes, Gustavo, da Motta Girardi, Daniel, Dib Batista Bugiato Faria, Luiza, Giacomini Bernardes, João Paulo, de Almeida Coudry, Renata

“…Metastatic gastric cancer (GC) is an incurable and aggressive disease with a poor prognosis. Immunotherapy is an attractive approach for treating patients with…”
Get full text

Hepatocellular Carcinoma: Review of Targeted and Immune Therapies by da Motta Girardi, Daniel, Correa, Tatiana Strava, Crosara Teixeira, Marcela, Dos Santos Fernandes, Gustavo

“…Background Hepatocellular carcinoma is the fifth most common cancer globally and the second leading cause of cancer-related mortality worldwide. Despite the…”
Get full text

Identification of radiologic and clinicopathologic variables associated with tumor regression pattern and distribution of cancer cells after short-course radiotherapy and consolidation chemotherapy in patients with rectal cancer by Gheller, Alexandre, Basílio, Dunya Bachour, da Costa, Marília Cristina Rosa, Tuma, Sussen Araújo, Ferreira, Oscar Miguel Túlio Andrade, Lyrio, Fernando Gonçalves, Girardi, Daniel da Motta, de Sousa, João Batista

“…Knowledge of the pattern of regression and distribution of residual tumor cells may assist in the selection of candidates for rectum-sparing strategies. To…”
Get full text

Perioperative chemotherapy with and without high-dose methotrexate in adult osteosarcoma by Negrão, Marcelo Vailati, da Silva Rocha, Lucila S, da Motta Girardi, Daniel, Feher, Olavo

“…Treatment of adult osteosarcoma (AOS) includes perioperative chemotherapy and surgery. Standard chemotherapy consists of cisplatin (CP) and doxorubicin (DOX)…”
Get full text

Acquired hemophilia A in a patient with advanced prostate cancer by Girardi, Daniel da Motta, Silva, Douglas Rafael Almeida, Villaça, Paula Ribeiro, Souza, Ciro Eduardo, da Fonseca, Leonardo Gomes, Bastos, Diogo Assed, Hoff, Paulo Marcelo Gehm

“…Acquired hemophilia A (AHA) is a rare disorder that results from the presence of autoantibodies against the clotting factor VIII (FVIII) causing hemorrhagic…”
Get full text

A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE) by Chandran, Elias, Simon, Nicholas I., Girardi, Daniel da Motta, Ley, Lisa, Wang, Tzu-fang, Kydd, Andre Rashad, Atiq, Saad Omar, Boudjadi, Salah, Stukes, Ian, Smith, Elizabeth, Akbulut, Dilara, Niglio, Scot Anthony, Gurram, Sandeep, Bilusic, Marijo, Steinberg, Seth M., Apolo, Andrea B

“…TPS4628 Background: Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) targeting nectin-4 with a monomethyl auristatin E (MMAE) payload, a potent…”
Get full text

Extreme bipolar androgen therapy with darolutamide and testosterone cypionate in patients with metastatic castration-resistant prostate cancer: ExBAT (LACOG 0620) trial by Isaacsson Velho, Pedro H, Girardi, Daniel da Motta, Soares, Andrey, Fontes Jardim, Denis Leonardo, Maluf, Fernando Cotait, Morbeck, Igor Alexandre, Dias, Mariane Fontes, Souza, Vinicius Carrera, Silva, Adriano Goncalves E, de Jesus, Rafaela Gomes, Rebelatto, Taiane Francieli, Bastos, Diogo Assed

“…TPS276 Background: Prostate cancer has an intrinsic dependence on androgens and androgen receptor (AR) regulation. Suppression of gonadal androgen synthesis…”
Get full text

A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies by Simon, Nicholas I., Niglio, Scot Anthony, Chandran, Elias, Iannantuono, Giovanni Maria, Boudjadi, Salah, Banday, Rouf, Girardi, Daniel da Motta, Cordes, Lisa M., Ley, Lisa, Gurram, Sandeep, Kydd, Andre Rashad, Jones, Jennifer C, Salerno, Kilian Elizabeth, Patel, Krishnan, Valera, Vladimir, Parnes, Howard L., Figg, William Douglas, Gulley, James L., Schlom, Jeffrey, Apolo, Andrea B.

“…4571 Background: Bintrafusp alfa is a novel bifunctional fusion protein targeting PD-L1 and TGF-β which has demonstrated clinical efficacy in some tumor types…”
Get full text

Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab by Iannantuono, Giovanni Maria, Chandran, Elias, Simon, Nicholas I., Ley, Lisa, Cordes, Lisa M., Wang, Tzu-fang, Girardi, Daniel da Motta, Gurram, Sandeep, Valera, Vladimir, Chalfin, Heather, Parnes, Howard L., Nadal, Rosa, Niglio, Scot Anthony, Boudjadi, Salah, Banday, Abdul Rouf, Kydd, Andre Rashad, Steinberg, Seth M., Apolo, Andrea B.

“…e16506 Background: Peripheral blood markers (PBM) have been demonstrated to be prognostic and/or predictive for cancer patients (pts) treated with immune…”
Get full text

Survival outcomes of metastatic castration-resistant prostate cancer in Brazil (LACOG 1818) by Maluf, Fernando Cotait, Martins, Suelen P. S., Silva Neto, Deusdedit Cortêz Vieira, Werutsky, Gustavo, Rinck Jr, Jose Augusto, Bastos, Diogo Assed, Rocha, Roberto Odebrecht, Fay, Andre P., Fernandes, Roni de Carvalho, Girardi, Daniel da Motta, Araujo, Daniel Vilarim, Mota, Augusto C. A., Lara Gongora, Aline Bobato, Fernandes, Bruno Melo, Alves, Ana Caroline Fonseca, Sampaio, Cristina de Deus Anjos Tavares, de Souza, Andréa Lopes Ponte, de Jesus, Rafaela Gomes, Gössling, Gustavo Cartaxo de Lima, Soares, Andrey

“…TPS272 Background: Treatment of metastatic castration-resistant prostate cancer (mCRPC) has been steadily evolving during the last decade, but access remains a…”
Get full text

A phase II study of the selective MET kinase inhibitor INC280 in advanced papillary renal cell cancer by Leger, Paul Denis, Girardi, Daniel da Motta, Al Harthy, Munjid, Friend, Julia C., Mac, Lisa, Purcell, Erin, Vocke, Cathy, Gurram, Sandeep, Merino, Maria J., Choyke, Peter, Linehan, W. Marston, Srinivasan, Ramaprasad

“…Abstract only 5075 Background: There are currently no approved systemic agents for patients with advanced type 1 papillary renal cell carcinoma (pRCC). Type 1…”
Get full text

A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies by Niglio, Scot Anthony, Girardi, Daniel da Motta, Cordes, Lisa M., Ley, Lisa, Mallek, Marissa, Sierra Ortiz, Olena, Cadena, Jacqueline, Diaz, Carlos, Chalfin, Heather, Kydd, Andre, Costello, Rene, Marciscano, Ariel E., Jones, Jennifer C, Salerno, Kilian Elizabeth, Valera, Vladimir, Figg, William Douglas, Dahut, William L., Gulley, James L., Schlom, Jeffrey, Apolo, Andrea B.

“…Abstract only TPS4599 Background: The majority of non- prostate genitourinary (GU) cancers are lethal when metastatic and rare GU cancers have limited…”
Get full text

A pilot clinical trial of genomic-based therapy assignment with co-expression extrapolation (COXEN) in advanced/metastatic urothelial carcinoma by Niglio, Scot Anthony, Nadal, Rosa Maria, Cordes, Lisa M., Steinberg, Seth M., Davarpanah, Nicole N., Costello, Rene, Mallek, Marissa, Girardi, Daniel da Motta, Merino, Maria, Wang, Yonghong, Mannheimer, Joshua, Edelman, Daniel, Walling, Jennifer, Meltzer, Paul S., Theodorescu, Dan, Gustafson, Daniel, Apolo, Andrea B.

“…Abstract only 452 Background: We investigated the Co-eXpression ExtrapolatioN (COXEN) algorithm to select “next best therapy” for patients with…”
Get full text

Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors by Apolo, Andrea B., Girardi, Daniel da Motta, Niglio, Scot Anthony, Nadal, Rosa Maria, Cordes, Lisa M., Steinberg, Seth M., Costello, Rene, Trepel, Jane B, Lee, Sunmin, Lee, Min-Jung, Cao, Liang, Gulley, James L., Bottaro, Donald P., Saraiya, Biren, Pal, Sumanta K., Quinn, David I., Lara, Primo "Lucky" N., Parnes, Howard L., Dahut, William L., Mortazavi, Amir

“…Abstract only 3 Background: CaboNivo and CaboNivoIpi showed promising efficacy and safety in a dose-escalation phase I study in patients (pts) with metastatic…”
Get full text

Differences in pathology and mutational status among colorectal cancer (CRC) patients pre-, post-, and during screening age by Fernandes, Gustavo Dos Santos, Pereira, Allan Andresson Lima, Braga, Gabriella Pereira, Gumz, Brenda Pires, Crosara Alves Texeira, Marcela, Mascarenhas, Cintia do Couto, Girardi, Daniel da Motta, Barrichello, Adriana Paula de Castro, Seidler, Heinrich

“…Abstract only 3596 Background: Screening protocols for CRC are broadly recommended and effective in reducing mortality. However, populations from different age…”
Get full text

Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy by Girardi, Daniel da Motta, Niglio, Scot Anthony, Mortazavi, Amir, Lara, Primo, Pal, Sumanta K., Saraiya, Biren, Cordes, Lisa M., Ley, Lisa, Sierra Ortiz, Olena, Cadena, Jacqueline, Diaz, Carlos, Bagheri, Mohammadhadi H., Steinberg, Seth M., Costello, Rene, Streicher, Howard, Wright, John, Parnes, Howard L., Ning, Yang-Min, Bottaro, Donald P., Apolo, Andrea B.

“…Abstract only 5037 Background: Previous treatment with ICI is more common in clinical practice since recent FDA-approval of 5 ICIs in second-line and 2 in…”
Get full text

Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi) by Niglio, Scot Anthony, Girardi, Daniel da Motta, Mortazavi, Amir, Lara, Primo, Pal, Sumanta K., Saraiya, Biren, Cordes, Lisa M., Ley, Lisa, Sierra Ortiz, Olena, Cadena, Jacqueline, Diaz, Carlos, Bagheri, Mohammadhadi H., Steinberg, Seth M., Costello, Rene, Streicher, Howard, Wright, John, Parnes, Howard L., Ning, Yang-Min, Bottaro, Donald P., Apolo, Andrea B.

“…Abstract only 5039 Background: We investigated challenging/re-challenging pts with ipilimumab (ipi) after progression on CaboNivo or CaboNivoIpi. Methods: In a…”
Get full text

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update by Soares, Andrey, Monteiro, Fernando Sabino Marques, da Trindade, Karine Martins, Silva, Adriano Gonçalves e, Cardoso, Ana Paula Garcia, Sasse, André Deeke, Fay, André P., Carneiro, André Paternò Castello Dias, Alencar Junior, Antonio Machado, de Andrade Mota, Augusto César, Santucci, Bruno, da Motta Girardi, Daniel, Herchenhorn, Daniel, Araújo, Daniel Vilarim, Jardim, Denis Leonardo, Bastos, Diogo Assed, Rosa, Diogo Rodrigues, Schutz, Fabio A., Kater, Fábio Roberto, da Silva Marinho, Felipe, Maluf, Fernando Cotait, de Oliveira, Fernando Nunes Galvão, Vidigal, Fernando, Morbeck, Igor Alexandre Protzner, Rinck Júnior, Jose Augusto, Costa, Leonardo Atem G. A., Maia, Manuel Caitano Dias Ferreira, Zereu, Manuela, Freitas, Marcelo Roberto Pereira, Dias, Mariane Sousa Fontes, Tariki, Milena Shizue, Muniz, Pamela, Beato, Patrícia Medeiros Milhomem, Lages, Paulo Sérgio Moraes, Velho, Pedro Isaacsson, de Carvalho, Ricardo Saraiva, Mariano, Rodrigo Coutinho, de Araújo Cavallero, Sandro Roberto, Oliveira, Thiago Martins, Souza, Vinicius Carrera, Smaletz, Oren, de Cássio Zequi, Stênio

“…Purpose Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and…”
Get full text

Perioperative chemotherapy with cisplatin (CP) and doxorubicin (DOX) with and without high-dose methotrexate (HDM) in adult osteosarcoma (AOT): Is methotrexate warranted? by Rocha, Lucila Soares Da Silva, Negrao, Marcelo Vailati, Girardi, Daniel da Motta, Camargo, Veridiana Pires De, Alban, Luciana Bastos Valente, Hoff, Paulo Marcelo, Feher, Olavo

“…Abstract only…”
Get full text

Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients by Fernandes, Gustavo Dos Santos, Braghiroli, Maria Ignez, Artioli, Michelle, Paterlini, Ana Carolina Carvalho Rocha, Teixeira, Marcela Crosara, Gumz, Brenda Pires, Girardi, Daniel da Motta, Braghiroli, Oddone F. M., Costa, Frederico Perego, Hoff, Paulo M.

“…Purpose Our objective was to evaluate the benefit of re-exposing patients with refractory metastatic colorectal cancer (mCRC) to a combination of oxaliplatin,…”
Get full text